Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer.

被引：0
|
作者：
Safonov, Anton Mikhailovich
Bandlamudi, Chaitanya
Selenica, Pier
Marra, Antonio
Ferraro, Emanuela
Mandelker, Diana
Solit, David B.
Berger, Michael F.
Norton, Larry
Powell, Simon N.
Shen, Ronglai
Robson, Mark E.
Chandarlapaty, Sarat
Reis-Filho, Jorge S.
Razavi, Pedram
机构：
[1] Hosp Univ Penn, Philadelphia, PA USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Milan, Italy
[4] Sloan Kettering Inst, Weill Cornell Med Coll, Kravis Ctr Mol Oncol, Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1010
引用
收藏
页数：1
相关论文
共 50 条
  • [41] CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)
    Huang, Jinyao
    Zheng, Liang
    Sun, Zicheng
    Li, Jie
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2022, 50 (04)
  • [42] Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer
    Andreas Bjerrum
    Andreas Frederik Henriksen
    Ann Søegaard Knoop
    Tobias Berg
    Ida Elisabeth Viller Tuxen
    Ulrik Lassen
    Tonny Studsgaard Petersen
    BJC Reports, 2 (1):
  • [43] Longitudinal, multimodal profiling of metastatic ER plus breast cancer on CDK4/6 inhibitor therapy
    Creason, Allison L.
    Egger, Julian
    Watson, Cameron
    Sivagnanam, Shamilene
    Lin, Jia-Ren
    Chin, Koei
    Sorger, Peter K.
    Coussens, Lisa M.
    Mitri, Zahi I.
    Gray, Joe W.
    Mills, Gordon B.
    Goecks, Jeremy
    CANCER RESEARCH, 2023, 83 (07)
  • [44] Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor
    Malon, Diego
    Molto, Consolacion
    Prasla, Shopnil
    Cuthbert, Danielle
    Pathak, Neha
    Berner-Wygoda, Yael
    Di Lorio, Massimo
    Li, Meredith
    Savill, Jacqueline
    Mittal, Abhenil
    Amir, Eitan
    Jhaveri, Kartik
    Nadler, Michelle B.
    BREAST CANCER RESEARCH AND TREATMENT, 2025, 210 (02) : 405 - 416
  • [45] Follicular Lymphoma Response with CDK4/6 Inhibitor(Palbociclib) Utilized in the Setting of Metastatic Breast Cancer
    Ali, Syed S.
    Mertens, Wilson
    BLOOD, 2017, 130
  • [46] CDK6 overexpression promotes resistance to CDK4/6 inhibitors in breast cancer
    Li, Qing
    Razavi, Pedram
    Li, Zhiqiang
    Paula, Arnaud F. Da Cruz
    Brogi, Edi
    Scaltriti, Maurizio
    Reis-Filho, Jorge S.
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2019, 79 (13)
  • [47] Mechanism of CDK4/6 Inhibitor Resistance in Hormone Receptor-positive Breast Cancer and Alternative Treatment Strategies
    Chang, Chun-Ming
    Lam, Ho Yin Pekkle
    ANTICANCER RESEARCH, 2023, 43 (12) : 5283 - 5297
  • [48] Treatment of RB1-intact cancers with CDK4/6 inhibitor combination therapy.
    Takahashi, Chiaki
    CANCER RESEARCH, 2021, 81 (13)
  • [49] The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
    Laura Morrison
    Sibylle Loibl
    Nicholas C. Turner
    Nature Reviews Clinical Oncology, 2024, 21 : 89 - 105
  • [50] Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HRD/HER2L metastatic breast cancer?
    Giordano, A.
    Lin, N. U.
    Tolaney, M.
    Mayer, L.
    ANNALS OF ONCOLOGY, 2024, 35 (01) : 10 - 14
12345